ホーム
マーケット
チャート&アイデア
Algo
ニュース
Store
ブローカー
ダウンロード
経済指標カレンダー
取引シグナル
Webターミナル
「
/
」を入力して検索:@user、$symbol
検索
ログイン
アカウントを作成
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SEER
#3273
Seer, Inc. Class A Common Stock
1.7
2
-16.50%
セクター:
ベース:
利益通貨:
日中レンジ
1年のレンジ
1日の変化
-16.50%
月次変化
-9.47%
6か月変化
-16.50%
1年の変化
-20.74%
以前の終値
2.0
6
Open
1.7
2
Bid
Ask
Low
1.7
2
High
1.7
2
ボリューム
15
マーケット
株
ヘルスケア
SEER
Open full chart
Financials
Overview
明細書
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2021
2022
2023
2024
Total assets
539.14 M
487.93 M
436.27 M
366.6 M
Total liabilities
36.22 M
40.94 M
39.37 M
39.03 M
Total equity
502.92 M
446.99 M
396.9 M
327.57 M
Total liabilities & shareholders' equities
539.14 M
487.93 M
436.27 M
366.6 M
Total debt
—
—
—
—
Net debt
—
—
—
—
Seer Inc - Class A
Seer, Inc. is an American biotechnology company headquartered in Redwood City, California. Established in 2017, the company develops technologies for proteomics research.
ニュース
Seer, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SEER) 2026-02-27
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Seer apresenta crescimento de 67% na base instalada, mas receita decepciona
Seer Q4 2025 slides: installed base surges 67%, revenue misses mark
Lucro da Seer superou projeções por $0,02; receita menor do que estimativas
Seer earnings beat by $0.02, revenue fell short of estimates
Seer apresentará tecnologia de proteômica em conferência nos EUA
Seer to showcase proteomics technology at US HUPO conference
Mass spectrometry study validates protein-gene associations for drug discovery
Seer, Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:SEER) 2025-11-26
Seer no Fórum CG MedTech: inovações em proteômica lideram o caminho
Seer at CG MedTech Forum: Proteomics Innovations Lead the Way